Navigation Links
FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
Date:6/5/2008

. 2007;

35:319-326.

3. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. for the HORIZON

Recurrent Fracture Trial. Zoledronic acid and clinical fractures and

mortality after hip fracture. N Engl J Med. 2007:537:1799-1809.

4. National Osteoporosis Foundation. Fast Facts on Osteoporosis Brochure.

February 2008.

5. U.S. Department of Health and Human Services. Bone Health and

Osteoporosis: A Report of the Surgeon General. 2004, p. 88.

6. Zometa(R) (zoledronic acid) Injection [Prescribing Information]. East

Hanover, NJ: Novartis Pharmaceuticals Corporation. March 2008.

Novartis

US Media Contacts

Jeanne Longo Anna Frable

Novartis Pharmaceuticals Novartis Pharmaceuticals

Corporation Corporation

862-778-1454 (office) 862-778-5388 (office)

201-572-1116 (mobile) 732-673-5262 (mobile)

jeanne.longo@novartis.com anna.frable@novartis.com

e-mail: media.relations@novartis.com

Novartis Investor Relations

Ruth Metzler- +41 61 324

Arnold 9980

Katharina +41 61 324 North America

Ambuehl 5316 Office

Pierre-Michel +41 61 324 Richard Jarvis +1 212 830

Bringer 1065 2433

John Gilardi +41 61 324 Jill Pozarek +1 212 830

3018 2445

Thomas +41 61 324 Edwin +1 212 830

Hungerbuehler 8425 Valeriano 2456

Isabella Zinck +41 61 324

7188

Central pho
'/>"/>

SOURCE Novartis
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
2. Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
3. ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication
4. More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL
5. ESBATechs Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
6. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
7. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
8. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
9. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
10. Study Shows Once-Yearly Reclast Better than Risedronate at Increasing Bone Mass in Patients With Osteoporosis Caused by Glucocorticoids
11. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
Post Your Comments:
*Name:
*Comment:
*Email: